A

Aker Biomarine ASA
OSE:AKBM

Watchlist Manager
Aker Biomarine ASA
OSE:AKBM
Watchlist
Price: 51.7 NOK -2.27% Market Closed
Market Cap: 4.5B NOK
Have any thoughts about
Aker Biomarine ASA?
Write Note

Intrinsic Value

The intrinsic value of one AKBM stock under the Base Case scenario is 68.84 NOK. Compared to the current market price of 51.7 NOK, Aker Biomarine ASA is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AKBM Intrinsic Value
68.84 NOK
Undervaluation 25%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Aker Biomarine ASA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AKBM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AKBM?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Food Products Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Aker Biomarine ASA

Provide an overview of the primary business activities
of Aker Biomarine ASA.

What unique competitive advantages
does Aker Biomarine ASA hold over its rivals?

What risks and challenges
does Aker Biomarine ASA face in the near future?

Summarize the latest earnings call
of Aker Biomarine ASA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aker Biomarine ASA.

Provide P/S
for Aker Biomarine ASA.

Provide P/E
for Aker Biomarine ASA.

Provide P/OCF
for Aker Biomarine ASA.

Provide P/FCFE
for Aker Biomarine ASA.

Provide P/B
for Aker Biomarine ASA.

Provide EV/S
for Aker Biomarine ASA.

Provide EV/GP
for Aker Biomarine ASA.

Provide EV/EBITDA
for Aker Biomarine ASA.

Provide EV/EBIT
for Aker Biomarine ASA.

Provide EV/OCF
for Aker Biomarine ASA.

Provide EV/FCFF
for Aker Biomarine ASA.

Provide EV/IC
for Aker Biomarine ASA.

Show me price targets
for Aker Biomarine ASA made by professional analysts.

What are the Revenue projections
for Aker Biomarine ASA?

How accurate were the past Revenue estimates
for Aker Biomarine ASA?

What are the Net Income projections
for Aker Biomarine ASA?

How accurate were the past Net Income estimates
for Aker Biomarine ASA?

What are the EPS projections
for Aker Biomarine ASA?

How accurate were the past EPS estimates
for Aker Biomarine ASA?

What are the EBIT projections
for Aker Biomarine ASA?

How accurate were the past EBIT estimates
for Aker Biomarine ASA?

Compare the revenue forecasts
for Aker Biomarine ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aker Biomarine ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aker Biomarine ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aker Biomarine ASA compared to its peers.

Compare the P/E ratios
of Aker Biomarine ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Aker Biomarine ASA with its peers.

Analyze the financial leverage
of Aker Biomarine ASA compared to its main competitors.

Show all profitability ratios
for Aker Biomarine ASA.

Provide ROE
for Aker Biomarine ASA.

Provide ROA
for Aker Biomarine ASA.

Provide ROIC
for Aker Biomarine ASA.

Provide ROCE
for Aker Biomarine ASA.

Provide Gross Margin
for Aker Biomarine ASA.

Provide Operating Margin
for Aker Biomarine ASA.

Provide Net Margin
for Aker Biomarine ASA.

Provide FCF Margin
for Aker Biomarine ASA.

Show all solvency ratios
for Aker Biomarine ASA.

Provide D/E Ratio
for Aker Biomarine ASA.

Provide D/A Ratio
for Aker Biomarine ASA.

Provide Interest Coverage Ratio
for Aker Biomarine ASA.

Provide Altman Z-Score Ratio
for Aker Biomarine ASA.

Provide Quick Ratio
for Aker Biomarine ASA.

Provide Current Ratio
for Aker Biomarine ASA.

Provide Cash Ratio
for Aker Biomarine ASA.

What is the historical Revenue growth
over the last 5 years for Aker Biomarine ASA?

What is the historical Net Income growth
over the last 5 years for Aker Biomarine ASA?

What is the current Free Cash Flow
of Aker Biomarine ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aker Biomarine ASA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aker Biomarine ASA

Current Assets 172.5m
Cash & Short-Term Investments 16.3m
Receivables 45.3m
Other Current Assets 110.9m
Non-Current Assets 637.6m
PP&E 102.2m
Intangibles 139.7m
Other Non-Current Assets 395.7m
Current Liabilities 41.1m
Accounts Payable 23.6m
Other Current Liabilities 17.5m
Non-Current Liabilities 413.5m
Long-Term Debt 164.7m
Other Non-Current Liabilities 248.8m
Efficiency

Earnings Waterfall
Aker Biomarine ASA

Revenue
305m USD
Cost of Revenue
-204.2m USD
Gross Profit
100.8m USD
Operating Expenses
-97.5m USD
Operating Income
3.3m USD
Other Expenses
-3.5m USD
Net Income
-200k USD

Free Cash Flow Analysis
Aker Biomarine ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Aker BioMarine reported $94 million in revenue for Q2, a 6% increase year-over-year, with an EBITDA of $29 million, up 35%. The sale of its Feed Ingredients business for $590 million will finalize in Q3, enabling an extraordinary dividend of NOK 35-45 per share. The Human Health Ingredients segment grew by 22%, with robust development expected to continue. However, Consumer Health Products faced inventory adjustments, impacting short-term performance. Aker BioMarine plans to streamline overhead costs and optimize their remaining human health and nutrition-focused business, aiming to maximize shareholder value by growing EBITDA and seeking optimal transaction timings.

What is Earnings Call?
Fundamental Scores

AKBM Profitability Score
Profitability Due Diligence

Aker Biomarine ASA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
ROIC is Increasing
Positive 1-Year Revenue Growth
37/100
Profitability
Score

Aker Biomarine ASA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

AKBM Solvency Score
Solvency Due Diligence

Aker Biomarine ASA's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
54/100
Solvency
Score

Aker Biomarine ASA's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AKBM Price Targets Summary
Aker Biomarine ASA

Wall Street analysts forecast AKBM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AKBM is 78.03 NOK with a low forecast of 73.73 NOK and a high forecast of 84 NOK.

Lowest
Price Target
73.73 NOK
43% Upside
Average
Price Target
78.03 NOK
51% Upside
Highest
Price Target
84 NOK
62% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AKBM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Oct 18, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Want to learn more about AKBM dividends?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for AKBM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Aker Biomarine ASA

Country

Norway

Industry

Food Products

Market Cap

4.5B NOK

Dividend Yield

87.04%

Description

Aker BioMarine AS operates as a biotech innovator and Antarctic krill-harvesting company which develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company is headquartered in Lysaker, Akershus. The company went IPO on 2020-07-06. The company consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.

Contact

AKERSHUS
Lysaker
Oksenoyveien 10, P.O. Box 496
+4724130000
www.akerbiomarine.com

IPO

2020-07-06

Employees

568

Officers

See Also

Discover More
What is the Intrinsic Value of one AKBM stock?

The intrinsic value of one AKBM stock under the Base Case scenario is 68.84 NOK.

Is AKBM stock undervalued or overvalued?

Compared to the current market price of 51.7 NOK, Aker Biomarine ASA is Undervalued by 25%.

Back to Top